Use of mTOR Kinase Inhibitors in Cancer and Rare Diseases
Customize your policy alerts
Sign up for all Premera Bluecross policy alerts
Know when Premera Bluecross releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs medical-necessity coverage and prior-authorization requirements for oral, topical, and intravenous mTOR kinase inhibitors used for selected cancers, tuberous sclerosis complex, lymphangioleiomyomatosis, and organ-transplant rejection prophylaxis under the pharmacy or medical benefit.
Generic Yulithira (everolimus) was added to the policy with the same coverage criteria as generic everolimus tablets.
The initial authorization period for all other reviews of oral and topical drugs listed in the policy was changed from 3 months to 6 months.
Metastatic endometrial carcinoma after prior therapy, with everolimus used in combination with letrozole, was added to coverage criteria.
Non-formulary exception review authorizations for all drugs listed in the policy may be approved for up to 12 months.
Listed medications must follow the applicable product's FDA dosage and administration instructions.
Brand Afinitor products require a prior trial of the corresponding generic everolimus formulation.
Generic Yulithira was added with the same coverage criteria as generic everolimus tablets.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.